TY - JOUR
T1 - Genetic and Phenotypic Features of the Five Known Polyaminopathies
T2 - A Critical Narrative Review
AU - VanSickle, Elizabeth A.
AU - Sarasua, Sara M.
AU - Lowe, Tracy
AU - Farrell, Christopher L.
AU - Boccuto, Luigi
AU - Schwartz, Charles
AU - Pegg, Anthony E.
AU - Peron, Angela
AU - Faundes, Victor
AU - Ganapathi, Mythily
AU - Chung, Wendy K.
AU - Ziegler, Alban
AU - Hofstede, Floris
AU - Prouteau, Clément
AU - Steindl, Katharina
AU - Olson, Colleen
AU - Devinsky, Orrin
AU - Mastracci, Teresa L.
AU - Casero, Robert A.
AU - Stewart, Tracy Murray
AU - Gilmour, Susan
AU - Koerner, Teri
AU - Kutler, Mary Jo
AU - Rajasekaran, Surender
AU - Michael, Julianne
AU - Bachmann, André S.
AU - Bupp, Caleb P.
N1 - Publisher Copyright:
© 2025 The Author(s). American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.
PY - 2026/5
Y1 - 2026/5
N2 - Polyaminopathies are a recently described family of rare genetic neurodevelopmental disorders. Polyaminopathies disrupt the biosynthesis of the primary polyamines: putrescine, spermidine, and spermine. Snyder–Robinson syndrome results from hemizygous loss-of-function variants in the spermine synthase (SMS) gene, resulting in decreased or complete loss of spermine synthase enzyme activity. Bachmann–Bupp syndrome results from heterozygous gain-of-function variants in the ornithine decarboxylase 1 (ODC1) gene, resulting in increased ornithine decarboxylase enzyme activity. Faundes–Banka syndrome results from heterozygous loss-of-function variants in the eukaryotic translation initiation factor 5A (EIF5A) gene, impairing eIF5A protein function. DHPS (deoxyhypusine synthase) deficiency is an autosomal recessive disease and results from bi-allelic hypomorphic variants in the deoxyhypusine synthase (DHPS) gene, which results in reduced deoxyhypusine synthase enzyme activity. Finally, DOHH (deoxyhypusine hydroxylase) disorder is an autosomal recessive disorder caused by bi-allelic loss-of-function variants in the deoxyhypusine hydroxylase (DOHH) gene, which causes decreased deoxyhypusine hydroxylase enzyme activity. Snyder–Robinson syndrome was first described in 1969, while the other four syndromes have only been identified in the past 7 years. A comprehensive phenotypic and genotypic description of these five syndromes is needed. We review the clinical and genetic features of these five polyaminopathies to create an inclusive clinical resource. A systematic keyword search strategy was used to identify all published cases in PubMed, Web of Science, and Scopus databases. The five known syndromes associated with the polyamine pathway share many similar clinical phenotypes, and yet patients with each syndrome present with distinctive syndromic features. This review will serve as a valuable resource for clinicians diagnosing and caring for patients with these rare polyaminopathies.
AB - Polyaminopathies are a recently described family of rare genetic neurodevelopmental disorders. Polyaminopathies disrupt the biosynthesis of the primary polyamines: putrescine, spermidine, and spermine. Snyder–Robinson syndrome results from hemizygous loss-of-function variants in the spermine synthase (SMS) gene, resulting in decreased or complete loss of spermine synthase enzyme activity. Bachmann–Bupp syndrome results from heterozygous gain-of-function variants in the ornithine decarboxylase 1 (ODC1) gene, resulting in increased ornithine decarboxylase enzyme activity. Faundes–Banka syndrome results from heterozygous loss-of-function variants in the eukaryotic translation initiation factor 5A (EIF5A) gene, impairing eIF5A protein function. DHPS (deoxyhypusine synthase) deficiency is an autosomal recessive disease and results from bi-allelic hypomorphic variants in the deoxyhypusine synthase (DHPS) gene, which results in reduced deoxyhypusine synthase enzyme activity. Finally, DOHH (deoxyhypusine hydroxylase) disorder is an autosomal recessive disorder caused by bi-allelic loss-of-function variants in the deoxyhypusine hydroxylase (DOHH) gene, which causes decreased deoxyhypusine hydroxylase enzyme activity. Snyder–Robinson syndrome was first described in 1969, while the other four syndromes have only been identified in the past 7 years. A comprehensive phenotypic and genotypic description of these five syndromes is needed. We review the clinical and genetic features of these five polyaminopathies to create an inclusive clinical resource. A systematic keyword search strategy was used to identify all published cases in PubMed, Web of Science, and Scopus databases. The five known syndromes associated with the polyamine pathway share many similar clinical phenotypes, and yet patients with each syndrome present with distinctive syndromic features. This review will serve as a valuable resource for clinicians diagnosing and caring for patients with these rare polyaminopathies.
KW - Bachmann–Bupp syndrome
KW - deoxyhypusine hydroxylase disorder
KW - deoxyhypusine synthase deficiency
KW - DHPS
KW - DOHH
KW - EIF5A
KW - Faundes-Banka syndrome
KW - ODC1
KW - SMS
KW - Snyder–Robinson syndrome
UR - https://www.scopus.com/pages/publications/105025419379
U2 - 10.1002/ajmga.70029
DO - 10.1002/ajmga.70029
M3 - Article
C2 - 41410504
AN - SCOPUS:105025419379
SN - 1552-4825
VL - 200
SP - 993
EP - 1003
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 5
ER -